6 Years Ago I Recommended That You Buy GW Pharma

Updated: Feb 5

In 2015, I was interviewed by Stock News Now "The Wall Street View" and I recommended GW Pharma as a good investment. My powers of prognostication proved to be Perplexingly Profound!

Jazz Pharmaceuticals (JAZZ) on Wednesday agreed to acquire GW Pharmaceuticals (GWPH) in a deal valued at $7.2 billion.

Under the terms of the agreement, Jazz will pay $220 per American depositary share of GW Pharmaceuticals, consisting of $200 in cash and $20 in Jazz ordinary shares. The deal is valued at $6.7 billion net of GW cash.

The transaction, which has been approved by the boards of both companies, is expected to close in the second quarter.

Seth Yakatan

Seth Yakatan

Known for solutions that yield results, Seth Yakatan has completed or advised on acquisitions and corporate finance transactions totaling over $3 billion. He is CEO of Katan Associates International—a financial strategy and merchant banking firm specializing in commercialization and asset monetization—especially those within life-science and e-commerce sectors.


Subscribe for News and Insights

Thanks for submitting!